Evidence map›Paper›PMID 37288839›Full record

ArticlemAbs

In-line product quality monitoring during biopharmaceutical manufacturing using computational Raman spectroscopy.

Jiarui Wang, Jingyi Chen, Joey Studts, Gang Wang

Abstract read
In one paragraph

Article in mAbs. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Review
  6. Review
  7. Article
  8. Article
  9. Article
  10. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Jiarui WangBoehringer Ingelheim Pharma GmbH/Co. KG, Biberach an der Riss, Germany.
Jingyi ChenBoehringer Ingelheim Pharma GmbH/Co. KG, Biberach an der Riss, Germany.
Joey StudtsBoehringer Ingelheim Pharma GmbH/Co. KG, Biberach an der Riss, Germany.
Gang WangBoehringer Ingelheim Pharma GmbH/Co. KG, Biberach an der Riss, Germany.ORCID 0009-0000-8262-2951

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The implementation of process analytical technologies is positioned to play a critical role in advancing biopharmaceutical manufacturing by simultaneously resolving clinical, regulatory, and cost challenges. Raman spectroscopy is emerging as a key technology enabling in-line product quality monitoring, but laborious calibration and computational modeling efforts limit the widespread application of this promising technology. In this study, we demonstrate new capabilities for measuring product aggregation and fragmentation in real-time during a bioprocess intended for clinical manufacturing by applying hardware automation and machine learning data analysis methods. We reduced the effort needed to calibrate and validate multiple critical quality attribute models by integrating existing workflows into one robotic system. The increased data throughput resulting from this system allowed us to train calibration models that demonstrate accurate product quality measurements every 38 s. In-process analytics enable advanced process understanding in the short-term and will lead ultimately to controlled bioprocesses that can both safeguard and take necessary actions that guarantee consistent product quality.

Indexed as

Biological ProductsBioreactorsCalibrationSpectrum Analysis, RamanTechnology, PharmaceuticalBiological Productsautomationclinical manufacturinghigh throughput process developmentliquid handling roboticsmachine learningprocess analytical technologyRaman spectroscopy

Identifiers

PMID37288839
PMCPMC10251777

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.